New gout drug aims to stop flare pain in 72 hours
NCT ID NCT07453004
First seen Mar 12, 2026 · Last updated May 08, 2026 · Updated 7 times
Summary
This study tests an experimental drug, punarlimab, for people with acute gouty arthritis. About 170 adults who have had at least three gout flares in the past year will receive either the new drug or an active comparator. The main goal is to see if punarlimab reduces pain within 72 hours of the first dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GOUTY ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.